Mesoblast completes Phase 3 low back pain trial treatment as pivotal readout approaches
· themarketherald.com.au
Mesoblast has completed treatment of 350 patients in its pivotal Phase 3 trial for chronic low back pain, with results expected in mid-2027.
Join our daily newsletter At The Bell to receive exclusive market insights
Mesoblast (ASX:MSB) has completed patient treatment in its pivotal Phase 3 trial of ...